ClinicalTrials.gg
CompletedNCT06748079Updated Aug 11, 2026

A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

A Phase 1 interventional study of TQC3721 inhalation powder and Placebo for TQC3721 inhalation powder in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
9th of 17
113 · median 113
Started
2024
with 5 others
Phase 1
7 of 17
none open now
Registered
11th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 9th largest by enrollment, is one of 6 that started in 2024, is one of 7 in phase 1, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation powder in Chronic Obstructive Pulmonary Disease(COPD) patients with single/multiple dose escalation.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 40-75 years old, male or female;
  2. During screening, according to the Global Oceanographic Library for Discovery (GOLD)guidelines (2024), patients diagnosed with stable moderate to severe should have Force Expiratory Volume in 1 second ()/ forced vital capacity (FVC)\<0.7 after inhaling bronchodilators; 40% ≤ FEV1 accounts for ≤ 80% of the expected value;
  3. When screening, after inhaling salbutamol aerosol for 4 times, there is a certain reversibility in the airway: the absolute value of FEV1 improves by more than 100ml;

4.1Applicable to Part 1: Being able to adjust the current COPD treatment or for COPD patients with initial treatment, prescribed bronchodilators, including Long-acting Muscarinic Antagonists (LAMA) and/or Long-acting β2-agonist (LABA) inhaled drugs, can be discontinued during the screening period after signing the form; 4.2 Applicable to Part 2: Being able to adjust the current COPD treatment or for COPD patients with initial treatment,LAMA inhaled drugs can be used during the lead-in period after signing the informed consent form;

5.The subject is able to discontinue Short acting Beta agonists (SABA) for at least 6 hours and Short acting Anticholinergic Agents (SAMA) for at least 8 hours; 6.Smoking history ≥ 10 pack years (pack years: number of packs per day multiplied by smoking years); 7.There is no evidence to suggest active respiratory and/or cardiovascular diseases other than COPD in clinical practice (such as uncontrolled hypertension); 8.No other related lung diseases or history of thoracic surgery; 9.The subjects were able to undergo reproducible FEV1 lung function testing according to the ATS/ERS 2005 standard during screening; 10. (BMI) is between 18-30kg/m2; 11.Participants must agree to use methods (such as birth control pills, condoms, or intrauterine devices) with sexual partners of childbearing age during the clinical trial period (screening period to 30 days after the last dose); 12) The subject is able to use a dry powder inhaler correctly for inhalation. 13) I have fully understood this study and voluntarily participated. I have signed the 'Informed Consent Form'.

Exclusion criteria

Exclusion Criteria:

1 . History or current clinical instability of heart, respiratory, endocrine, metabolic, renal, liver, gastrointestinal, skin, infection, blood system, nervous system, or neurological/psychiatric disorders/abnormalities; 2. The result of the (HIV) antibody test is positive; The result of surface antigen (HBsAg) test is positive (if HBsAg is positive, Hepatitis B virus deoxyribonucleic acid (HBV-DNA) should be checked if necessary, and if HBV-DNA\<Lower Limit of Quantification (LLOQ), it does not need to be excluded); virus (HCV) antibody positive and confirmed presence of HCV ribonucleic acid (RNA); Positive for Treponema pallidum antibody (TPPA); 3. Have a history of illegal drug abuse in the past; 4. Have participated in other clinical trials and received the drug within 3 months prior to participating in this trial, or within 5 half lives of the investigational drug, whichever is shorter; 5. Those who have lost blood or donated more than 400 mL of blood within 2 months before the experiment; 6. Have any clear and severe history of drug or food allergies, especially those who are allergic to ingredients similar to the investigational drug; 7. Drinking history (drinking 14 units of alcohol per week: 1 unit=285 ml of beer; or 25 ml of spirits; or 1 glass of wine); 8. History of malignant tumors in any organ system within the past 5 years, regardless of whether treatment has been received or not, except for local basal cell carcinoma of the skin; 9. Lower respiratory tract infection occurred within 6 weeks before screening or randomization. Upper respiratory tract infections requiring antibiotics within 6 weeks prior to screening or randomization; 10. Have a history of active tuberculosis, bronchiectasis, asthma or other non-specific lung diseases.

11. (corrected QT interval, Fridericia formula QT [msec]/RR [s]) interval, male>450ms, female>470ms, or history of long QT syndrome before screening or randomization; 12. Subjects with a history of drug use in the past 2 years; 13. Subjects who are unable to comply with past medication and concomitant medication restrictions; 14. If there is a history of acute exacerbation of within 3 months before screening or randomization, hospitalization or additional COPD maintenance treatment is required. Over the past three years, the average number of frequent exacerbations of COPD with moderate to severe severity has been ≥ 2 per year, or resulting in hospitalization for ≥ 2 acute exacerbations per year; 15. Oral non selective beta blockers; 16. Previously treated with TQC3721 suspension. 17. Any situation that researchers believe may pose safety risks to subjects in the trial or may interfere with the conduct of this study, or where researchers believe that subjects may not be able to complete this study or may not be able to comply with the requirements of this study (due to management or other reasons).

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    TQC3721 inhalation powder

    TQC3721 inhalation powder is administered as a single dose or continuously for 7 days.

    Drug: TQC3721 inhalation powder

  • Placebo comparator
    Placebo for TQC3721 inhalation powder

    Placebo for TQC3721 inhalation powder inhalation is administered as a single dose or continuously for 7 days.

    Drug: Placebo for TQC3721 inhalation powder

  • Experimental
    TQC3721 Inhaler Powder + Glimetrexate Inhaler Powder / Control Group

    TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group for 14 consecutive days of inhalation administration.

    Drug: TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group

Interventions

  • TQC3721 is a target inhibitor.

  • DrugPlacebo for TQC3721 inhalation powder

    Placebo without drug substance.

  • DrugTQC3721 inhalation powder combined with glyberlam inhalation powder or a control group

    TQC3721 is a target inhibitor

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    Incidence of adverse events (AE)

    Time frame: 21 days

  2. Serious Adverse Events (SAE)

    Incidence of Serious Adverse Events (SAE)

    Time frame: 21 days

  3. Treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 19 days

Secondary outcomes

  1. Plasma drug peak concentration

    Plasma drug peak concentration after administration.

    Time frame: 9 days

  2. COPD Assessment Tes (CAT) scores

    CAT score after administration. The score range is 0 to 40 points (0 to 10 is minor influence; 11 to 20 are moderate; 21 to 30 are classified as severe impact; 31 to 40 is very severe).

    Time frame: From day 1 to day 11 or end of treatment, whichever came first

  3. PD indices: Pulmonary function test parameters

    CAT scores of COPD patients after multiple doses of TQC3721 DPI

    Time frame: From D-1 to End of Treatment(EOT).

  4. Serum and sputum inflammatory cells

    Changes in inflammatory cells in serum and sputum following treatment

    Time frame: From D-1 to D11 or End of EOT)

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2026, 20 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 20 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartActual
Dec 3, 2024
Primary completionActual
Aug 7, 2026
CompletionActual
Aug 7, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06748079
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Dec 3, 2024
Primary completion
Aug 7, 2026
Completion
Aug 7, 2026
Last update
Aug 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion